Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice
- PMID: 9303387
- PMCID: PMC164038
- DOI: 10.1128/AAC.41.9.1933
Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice
Abstract
We investigated the efficacy of trovafloxacin, a new quinolone, in comparison with that of clindamycin in the treatment of intra-abdominal abscesses caused by Bacteroides fragilis in young and senescent mice. The development of abscess formation, the number of viable organisms, and antibiotic concentrations were measured, and the values for young and old mice were compared. Trovafloxacin was well distributed to the tissues in both young and old animals. Although the pharmacokinetics and concentrations of trovafloxacin in serum were similar between young and old mice, the levels in tissue were higher in senescent mice than in young mice. Trovafloxacin therapy sterilized abscesses in 94% of young mice and in 73% of old mice, but this difference was not significant. This therapeutic response to trovafloxacin was similar to that seen with clindamycin. These results suggest that aging may not have any adverse effect on the therapeutic outcome for intra-abdominal abscesses caused by B. fragilis.
Similar articles
-
In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.Antimicrob Agents Chemother. 1997 Mar;41(3):583-6. doi: 10.1128/AAC.41.3.583. Antimicrob Agents Chemother. 1997. PMID: 9055997 Free PMC article.
-
Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection.Am J Surg. 1998 Dec;176(6A Suppl):39S-45S. doi: 10.1016/s0002-9610(98)00219-0. Am J Surg. 1998. PMID: 9935256
-
Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection.Int J Antimicrob Agents. 1999 Jul;12(2):135-9. doi: 10.1016/s0924-8579(99)00062-x. Int J Antimicrob Agents. 1999. PMID: 10418758
-
Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?Am J Health Syst Pharm. 1997 Nov 15;54(22):2569-84. doi: 10.1093/ajhp/54.22.2569. Am J Health Syst Pharm. 1997. PMID: 9397218 Review.
-
The chemistry and biological profile of trovafloxacin.J Antimicrob Chemother. 1997 Jun;39 Suppl B:1-14. doi: 10.1093/jac/39.suppl_2.1. J Antimicrob Chemother. 1997. PMID: 9222064 Review.
Cited by
-
Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.Antibiotics (Basel). 2017 Nov 7;6(4):26. doi: 10.3390/antibiotics6040026. Antibiotics (Basel). 2017. PMID: 29112154 Free PMC article. Review.
-
Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.Antimicrob Agents Chemother. 2005 Oct;49(10):4234-9. doi: 10.1128/AAC.49.10.4234-4239.2005. Antimicrob Agents Chemother. 2005. PMID: 16189103 Free PMC article.
-
Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.Biomedicines. 2024 Jan 19;12(1):227. doi: 10.3390/biomedicines12010227. Biomedicines. 2024. PMID: 38275398 Free PMC article. Review.
-
Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines.Antimicrob Agents Chemother. 2004 Jun;48(6):1974-82. doi: 10.1128/AAC.48.6.1974-1982.2004. Antimicrob Agents Chemother. 2004. PMID: 15155187 Free PMC article.
-
In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.Antimicrob Agents Chemother. 2001 May;45(5):1394-401. doi: 10.1128/AAC.45.5.1394-1401.2001. Antimicrob Agents Chemother. 2001. PMID: 11302801 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical